Navigation Links
King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
Date:8/30/2007

l context of the program in order to determine next steps related to the further development of bremelanotide for the treatment of ED.

About ED

ED is defined as the consistent inability to attain and maintain an erection sufficient for sexual intercourse. The condition is correlated with increasing age, cardiovascular disease, hypertension, diabetes, hyperlipidemia, and smoking. In addition, certain prescription drugs and psychogenic issues may contribute to ED. It is estimated that some degree of ED affects one half of all men over the age of 40 and that 150 million men worldwide suffer from ED.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. Palatin's internal research and development capabilities, anchored by its proprietary MIDAS(TM) technology, are fueling product development. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. To date, Palatin has entered into collaborations with AstraZeneca, King Pharmaceuticals, and Tyco Healthcare Mallinckrodt. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.

About King Pharmaceuticals, Inc.

King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing and product life-cycle management.


'/>"/>
SOURCE Palatin Technologies, Inc.; King Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2, 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) ... year ended December 31, 2014 on March 9, 2015. The Company ... on Thursday, March 12, 2015, at 5:00 pm ET. The call ...   , , , LIVE CALL:  ... code 92238648. , , , , ...
(Date:3/1/2015)... Telbec/ -   Ergoresearch Ltd (TSXV: ERG) – based ... the « Équilibre, orthèses et biomécanique» banner  – ... December 31, 2014. All dollar amounts in the present ... for the second quarter of fiscal year 2015 ended ... 8,8 % compared to revenues of $ 4 489 330 ...
(Date:3/1/2015)... 2015  USPlabs has notified the Food and ... that media reports saying that a company product ... February 28, 2015, the Center for Drug Evaluation ... the contamination of a dietary supplement product labeled ... as "OEP") with a prescription drug active ingredient, ...
Breaking Medicine Technology:ImmunoCellular Therapeutics to Report 2014 Financial Results on March 9, 2015; a Business Update Conference Call and Webcast is Scheduled for March 12, 2015 2Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 2Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 3Second Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended December 31, 2014. 4OEP Product Is Counterfeit 2
(Date:3/2/2015)... The minimally invasive surgical instruments ... of 6.1% to reach $14,133.0 million by 2019 ... such as advantages of minimally invasive surgeries over ... minimally invasive surgeries and increasing number of surgical ... global minimally invasive surgical instruments market. , For ...
(Date:3/2/2015)... March 02, 2015 Atlantic Information Services, ... AIS’s Directory of Health Plans: 2015 , the ... on the U.S. health plan market, with enrollment data ... United States. , Available as a printed book ... enrollment trends in quick-view tables and charts, as well ...
(Date:3/2/2015)... March 02, 2015 In light of ... anticoagulant Xarelto (rivaroxaban) tablets, Ford & Associates ... be helpful for future users, but may come too ... from taking the drug. The FDA has now included ... Adverse Reactions on Xarelto's label. The term “cytolytic hepatitis” ...
(Date:3/2/2015)... ProvidaStaff has announced today that ... division to EDU Healthcare to reflect better ... systems and students nationwide. , “ProvidaStaff has always been ... the country,” said Angela M. Lewis, President of ProvidaStaff. ... and the introduction of EDU Healthcare better aligns our ...
(Date:3/1/2015)... To help healthcare organizations ... practices compliantly and profitably, MDreferralPRO and Vericle ... The interoperability between a strategic referral management ... management system is necessary for a healthcare ... referral management and development solution relies on ...
Breaking Medicine News(10 mins):Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 3Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 4Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 3Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 2Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 3Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 4
... ... WAYNE, Pa., Nov. 13 Escalon Medical Corp.,(Nasdaq: ESMC ... 2008., For the first quarter of fiscal 2009, the Company ... This,included product revenue of $8,669,000 for the first quarter of fiscal,2009, ...
... Nov. 13 The fourth annual EagleBank,Foundation Fight ... local hospitals were the primary beneficiaries: Shady Grove,Adventist ... and The,George Washington University Hospital, Providence Hospital and ... the Primary Care,Coalition of Montgomery County. The tournament ...
... FORT LAUDERDALE, Fla., Nov. 13 eDiets.com,Inc. (Nasdaq: ... fitness,and healthy lifestyle solutions, today announced results for the ... Revenues for the third quarter of 2008 were $4.8 ... Net loss for the quarter was $(3.2),million, or $(0.13) ...
... urging safe sex practices, study says , , THURSDAY, ... for pelvic inflammatory disease (PID) become highly vulnerable ... or months after treatment, researchers at Johns Hopkins ... the researchers, suggest that treating PID "with a ...
... Nov. 13 Watson,Pharmaceuticals, Inc. (NYSE: ... announced that its New Drug Application (NDA) ... a luteinizing hormone,releasing hormone (LHRH) agonist, has ... and Drug Administration (FDA). Watson is seeking ...
... 13 In a regular session of,the New York ... the cover of,a contentious election year and an economic ... Appeals (NYCOA) declined to hear the appeal of,Kathryn Jordan ... by a woman with Multiple Sclerosis. The appeal was,filed ...
Cached Medicine News:Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 2Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 3Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 4Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 5Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 6Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 7Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 8Health News:Fourth Annual EagleBank Foundation Fight Breast Cancer Golf Classic Raises Over $100,000 2Health News:eDiets.com(R) Announces Q3 2008 Results 2Health News:eDiets.com(R) Announces Q3 2008 Results 3Health News:eDiets.com(R) Announces Q3 2008 Results 4Health News:eDiets.com(R) Announces Q3 2008 Results 5Health News:eDiets.com(R) Announces Q3 2008 Results 6Health News:eDiets.com(R) Announces Q3 2008 Results 7Health News:Pelvic Inflammation Puts Girls at Risk for Repeat STIs 2Health News:Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer 2Health News:Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer 3Health News:Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer 4Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 2Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 3Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 4Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 5
... Graft, the newest vascular graft offering from ... in vascular surgical products for more than ... kinking and compression problems that can ... provides all of the benefits of a ...
... The drilling and rasping necessary in cruciate ... roughness on the bone surface. This condition, ... can damage the cruciate replacement. The GORE ... cruciate ligament reconstruction procedures. The tool functions ...
Vikingselect™ Intra-Operative Monitoring (IOM)....
... has been designed by practicing neurophysiologists ... the ever changing and demanding medical ... data from multiple modalities, including: SSEPs ... multiple patients at multiple sites. Our ...
Medicine Products: